We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Metagenomics Enables Rapid Respiratory Infection Testing in ICU Patients

By LabMedica International staff writers
Posted on 28 Feb 2024
Print article
Image: Genetic testing offers potential for faster diagnosis for patients with infectious respiratory conditions (Photo courtesy of 123RF)
Image: Genetic testing offers potential for faster diagnosis for patients with infectious respiratory conditions (Photo courtesy of 123RF)

Patients with respiratory infectious diseases admitted to intensive care units urgently need appropriate medication, yet microbiologists typically require around three days to identify the responsible pathogens. Now, a new technology could offer a faster diagnostic solution for patients struggling with respiratory infections.

Researchers from Guy’s and St Thomas’ NHS Foundation Trust (GSTT, London, UK) have trialed a new technology that accelerates the genetic testing process for patients with suspected respiratory infectious diseases. This advanced approach, known as metagenomics, sequences genetic material from a comprehensive range of microorganisms, including bacteria, viruses, and fungi, potentially responsible for the infection. Remarkably, results are available in just seven hours, enabling same-day administration of accurate and effective treatments.

Unlike other tests, metagenomic testing can detect all present microorganisms, not limited to those specifically being sought or suspected by clinicians of causing the infection. The researchers have secured additional funding to extend this rapid genetic testing to a broader patient base. This expansion builds upon the initial successful pilot, which demonstrated its potential to enhance treatment for nearly half of the participants. The new funding will facilitate the implementation of this technology in multiple hospitals across the UK over the next two years. The aim is to monitor and curtail the spread of respiratory diseases, ultimately aiding in the prevention of new outbreaks.

“It is vital that the sickest patients in our intensive care unit receive the right medication as quickly as possible,” said Ian Abbs, Chief Executive at Guy’s and St Thomas’ and Co-Chair of the South East Genomic Medicine Service. “This new genetic test can make that happen and we are delighted that we now have funding to ensure other intensive care units, and their patients, can also benefit.”

Related Links:
GSTT

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.